10.2174/156802606775270288
10.4049/jimmunol.167.6.3182
10.1016/0167-0115(92)90519-Z
10.1016/S0167-0115(02)00167-2
10.1016/j.molbrainres.2005.03.016
10.1046/j.1460-9568.1999.00811.x
10.1046/j.0953-816X.2000.01345.x
10.1016/0378-1119(95)00391-I
Ait-Ali, D , Stroth, N, Sen, JM Eiden, LE (2009) PACAP-cytokine interactions govern adrenal neuropeptide biosynthesis after systemic administration of LPS. Neuropharmacologydoi:10.1016/j.neuropharm.2009.07.034.
2005, Endocrinology, 146, 744, 10.1210/en.2004-0504
2000, Ann N Y Acad Sci, 921, 300, 10.1111/j.1749-6632.2000.tb06981.x
10.1002/(SICI)1096-9861(20000529)421:2<234::AID-CNE8>3.0.CO;2-S
10.1111/j.1460-9568.2007.05535.x
10.1097/00006676-199401000-00018
1991, J Auton Pharmacol, 11, 285, 10.1111/j.1474-8673.1991.tb00252.x
10.1016/S0006-8993(98)00176-0
1994, Biomed Pept Proteins Nucleic Acids, 1, 45
10.1016/0024-3205(94)00423-P
10.1016/0014-2999(95)00404-9
10.1016/S0015-0282(97)00370-1
10.1095/biolreprod57.5.1074
10.1095/biolreprod66.3.830
10.1016/0014-2999(92)90217-R
10.1016/0006-8993(94)91592-X
1992, Regul Pept, 37, 287
10.1016/j.peptides.2007.06.006
10.1182/blood-2005-03-1186
10.1016/j.neuroscience.2007.09.084
10.1016/S0008-6363(95)00142-5
10.1016/j.peptides.2004.05.013
1997, J Mol Neurosci, 9, 211, 10.1007/BF02800503
2000, Am J Physiol Gastrointest Liver Physiol, 279, G1048, 10.1152/ajpgi.2000.279.5.G1048
10.1016/j.ygcen.2006.12.022
10.1007/s12031-008-9059-5
10.1111/j.1471-4159.2006.04148.x
10.1016/j.nbd.2008.06.014
10.1016/j.peptides.2009.03.011
2005, Neurotox Res, 8, 227, 10.1007/BF03033976
10.1016/S0143-4179(96)90041-4
2003, Anat Embryol, 206, 319, 10.1007/s00429-002-0294-1
2004, J Cereb Blood Flow Metab, 24, 628, 10.1097/01.WCB.0000121234.42748.F6
1993, J Androl, 14, 170, 10.1002/j.1939-4640.1993.tb00374.x
10.1016/j.regpep.2006.03.010
1995, J Neurochem, 65, 1318, 10.1046/j.1471-4159.1995.65031318.x
10.1016/0165-3806(94)90150-3
10.1016/0306-4522(93)90066-O
10.1002/1096-9861(20001002)425:4<495::AID-CNE3>3.0.CO;2-A
2000, Ann N Y Acad Sci, 921, 304, 10.1111/j.1749-6632.2000.tb06982.x
10.1016/j.expneurol.2003.07.007
10.1016/j.bmcl.2008.01.052
1995, Exp Clin Endocrinol Diabetes, 103, 386
10.1046/j.1460-9568.2003.03000.x
1996, Br J Pharmacol, 117, 764, 10.1111/j.1476-5381.1996.tb15256.x
10.1016/0196-9781(84)90231-6
10.1016/0006-8993(86)91493-9
10.1152/ajpregu.00078.2006
10.1111/j.1471-4159.2004.02498.x
10.1016/j.jneuroim.2006.04.013
10.1016/j.regpep.2006.12.010
10.1016/0196-9781(93)90154-9
10.1016/0196-9781(94)90206-2
10.1016/j.cellsig.2006.12.006
10.1016/0092-8674(88)90037-2
10.1016/j.ygeno.2006.07.008
10.1016/j.peptides.2007.04.013
10.1007/s12031-008-9075-5
10.1016/0167-0115(91)90044-H
10.1016/j.peptides.2008.01.022
Bourgault, S , Vaudry, D, Dejda, A, Doan, ND, Vaudry, H Fournier, A (2009a) Pituitary adenylate cyclase-activating polypeptide: focus on structure-activity relationships of a neuroprotective peptide. Curr Med Chem,in press.
10.1007/s12031-008-9081-7
10.1016/S0306-4522(98)00290-5
2001, Mol Brain Res, 90, 149, 10.1016/S0169-328X(01)00097-3
1994, Neuroendocrinology, 60, 493, 10.1159/000126786
10.1002/(SICI)1521-4141(199810)28:10<3120::AID-IMMU3120>3.0.CO;2-3
1998, J Neurosci, 18, 9766, 10.1523/JNEUROSCI.18-23-09766.1998
1997, J Neurosci, 17, 4045, 10.1523/JNEUROSCI.17-11-04045.1997
2000, Ann N Y Acad Sci, 921, 429, 10.1111/j.1749-6632.2000.tb07010.x
1998, Endocr Res, 24, 961, 10.3109/07435809809032716
10.1016/0006-8993(94)91303-X
10.1016/S0143-4179(02)00045-8
10.1016/S0143-4179(03)00022-2
2006, Front Horm Res, 35, 102
1997, J Vasc Res, 34, 11, 10.1159/000159197
1992, Gastroenterology, 103, 1002, 10.1016/0016-5085(92)90035-W
10.1016/0014-5793(90)80158-F
1999, Am J Physiol, 277, 42
10.1016/S0196-9781(03)00058-5
10.1523/JNEUROSCI.4361-04.2005
10.1016/S0006-8993(98)01044-0
1995, Cytogenet Cell Genet, 71, 193, 10.1159/000134105
10.1002/1096-9861(20000717)423:1<26::AID-CNE3>3.0.CO;2-C
10.1016/0196-9781(86)90209-3
10.1016/j.neuroscience.2007.02.025
Cameron, DC , Raoult, E, Galas, L, Jiang, Y, Lee, K, Hu, T, Vaudry, D Komuro, H (2009) Role of PACAP in controlling granule cell migration. Cerebellumdoi: 10.1007/s12311-009-0121-9.
1992, Growth Regul, 2, 175
10.1111/j.1749-6632.1996.tb23163.x
10.1016/0167-0115(91)90071-N
10.1016/j.peptides.2007.05.016
2002, J Neurosci, 22, 1583, 10.1523/JNEUROSCI.22-05-01583.2002
10.1016/0167-0115(96)00032-8
2005, J Endocrinol Invest, 28, 10
10.1016/0196-9781(90)90194-A
10.1016/0167-0115(91)90478-Y
1996, Mol Pharmacol, 50, 60
1995, Mol Pharmacol, 48, 56
10.1111/j.0953-816X.2004.03138.x
10.1523/JNEUROSCI.0215-08.2008
1998, Am J Physiol, 275, G769
1998, Endocr Res, 24, 943, 10.3109/07435809809032712
10.1016/S0304-3940(96)12468-X
10.1016/j.regpep.2005.02.012
1998, Neurobiology, 6, 45
10.1111/j.1365-2826.2008.01718.x
10.1016/j.neulet.2005.04.070
10.1016/j.regpep.2006.06.016
10.1016/0014-2999(93)90170-M
10.1016/S0303-7207(01)00480-4
1995, J Neurochem, 64, 2111, 10.1046/j.1471-4159.1995.64052111.x
1996, FASEB J, 10, 1310, 10.1096/fasebj.10.11.8836045
1997, J Neurochem, 68, 1078, 10.1046/j.1471-4159.1997.68031078.x
2007, Exp Biol Med, 232, 262
1987, J Neurosci, 7, 357, 10.1523/JNEUROSCI.07-02-00357.1987
10.1016/S0169-328X(00)00116-9
10.1016/S0196-9781(99)00067-4
10.1016/0306-4522(94)90092-2
1993, Biochim Biophys Acta, 1154, 183, 10.1016/0304-4157(93)90011-C
10.1016/0196-9781(81)90040-1
10.1016/0196-9781(86)90171-3
10.1016/S0169-328X(99)00116-3
1994, J Neurosci, 14, 7141, 10.1523/JNEUROSCI.14-11-07141.1994
2005, Int J Oncol, 26, 1629
10.1152/ajpregu.00200.2003
2004, Am J Physiol Regul Integr Comp Physiol, 287, R1194, 10.1152/ajpregu.00268.2004
2009, Biochim Biophys Acta, 1788, 1556, 10.1016/j.bbamem.2008.09.018
10.1016/0143-4179(95)90013-6
1990, Am J Pathol, 137, 605
1998, J Neurochem, 71, 478, 10.1046/j.1471-4159.1998.71020478.x
10.1016/j.peptides.2007.05.011
1986, J Biol Chem, 261, 14482, 10.1016/S0021-9258(18)66895-4
10.1111/j.1471-4159.1986.tb00780.x
10.1016/S0016-6480(03)00284-3
10.1016/S0303-7207(02)00028-X
10.1113/jphysiol.2003.052514
10.1046/j.1460-9568.2003.02425.x
1998, Mol Brain Res, 54, 161, 10.1016/S0169-328X(97)00335-5
10.1111/j.1460-9568.1996.tb01215.x
1999, Development, 126, 3089, 10.1242/dev.126.14.3089
2003, J Neurosci, 23, 8949, 10.1523/JNEUROSCI.23-26-08949.2003
10.1016/S0028-3908(00)00167-2
10.1046/j.1365-2826.1999.00411.x
10.1097/00007890-199901150-00028
10.1016/0304-3940(85)90116-8
10.1007/s12031-008-9087-1
2005, Pharmacol Rep, 57, 307
10.1016/S0006-291X(02)00283-8
10.4049/jimmunol.164.3.1200
10.1016/S0165-5728(00)00359-3
10.4049/jimmunol.166.2.1028
10.1016/0165-5728(95)00105-6
10.1016/S0196-9781(96)00171-4
1996, Blood, 87, 5152, 10.1182/blood.V87.12.5152.bloodjournal87125152
10.1002/1521-4141(200011)30:11<3236::AID-IMMU3236>3.0.CO;2-L
10.1016/S0165-5728(99)00105-8
1999, J Immunol, 163, 3629, 10.4049/jimmunol.163.7.3629
Delgado, M , Leceta, J Gomariz, RPVaudry, H, Arimura, A & Melmed, S (2002c) Function of PACAP in the immune system, inPituitary Adenylate Cyclase-Activating PolypeptideAmsterdam.Kluwer Academic Publishers,305–322,
10.1016/0165-5728(96)00063-X
1999, J Immunol, 162, 1200, 10.4049/jimmunol.162.2.1200
1999, J Immunol, 162, 1707, 10.4049/jimmunol.162.3.1707
1999, J Immunol, 162, 4685, 10.4049/jimmunol.162.8.4685
10.1016/S0165-5728(99)00023-5
10.1016/0167-0115(96)00024-9
1999, J Immunol, 162, 2358, 10.4049/jimmunol.162.4.2358
1999, J Immunol, 163, 4213, 10.4049/jimmunol.163.8.4213
Deguil, J , Chavant, F, Lafay-Chebassier, C, Pérault-Pochat, MC, Fauconneau, B Pain, S (2009)Neuroprotective Effect of PACAP on translational control alteration and cognitive decline in MPTP parkinsonian mice. Neurotox Resdoi: 10.1007/s12640-009-9091-4
10.1016/0303-7207(94)90143-0
1992, J Biol Chem, 267, 5108, 10.1016/S0021-9258(18)42737-8
1999, J Neurosci, 19, 8740, 10.1523/JNEUROSCI.19-20-08740.1999
10.1016/s0304-3940(02)01316-2
10.1111/j.1749-6632.1998.tb11188.x
10.1016/S0165-6147(99)01340-1
10.1016/j.pharmthera.2008.11.006
10.1016/j.neuropharm.2006.07.017
10.1016/S0167-0115(02)00190-8
10.1016/0092-8674(90)90095-V
1997, J Neurosci, 17, 563, 10.1523/JNEUROSCI.17-02-00563.1997
10.1016/j.neulet.2008.08.060
10.1016/0024-3205(96)00299-8
10.1016/j.neuroscience.2006.05.065
10.1016/0006-8993(96)00139-4
10.1016/0306-4522(96)00057-7
10.1016/j.brainres.2007.10.015
10.1016/0092-8674(83)90210-6
2002, J Neurophysiol, 88, 1374, 10.1152/jn.2002.88.3.1374
1994, Am J Physiol, 266, E870, 10.1152/ajpcell.1994.266.3.C870
1997, Exp Physiol, 82, 717, 10.1113/expphysiol.1997.sp004060
10.1146/annurev.ne.15.030192.000421
10.1016/S0167-0115(99)00080-4
10.1016/S0014-2999(97)01144-8
10.1016/S0303-7207(98)00047-1
10.1095/biolreprod58.1.116
1997, Acta Ophthalmol Scand, 75, 159, 10.1111/j.1600-0420.1997.tb00114.x
1980, Neuroendocrinology, 31, 200, 10.1159/000123074
10.1016/j.mce.2004.01.013
10.1113/jphysiol.2004.070060
10.1016/0196-9781(93)90136-5
10.1016/0306-4522(96)00082-6
10.1016/S0306-4522(97)00474-0
10.1016/0167-0115(95)00052-D
Fahrenkrug, J , Hannibal, J Gräs, SVaudry, H, Arimura, A & Melmed, S (2003) PACAP in the urogenital tract, in Pituitary Adenylate Cyclase-Activating PolypeptideAmsterdam.Kluwer Academic Publishers,251–275,
10.1111/j.1471-4159.2004.02810.x
10.1016/0006-8993(95)00443-T
1983, Pharmacol Rev, 35, 181
10.1016/j.regpep.2004.05.014
10.1152/ajpregu.00753.2007
1995, Neuroendocrinology, 61, 377, 10.1159/000126859
10.1016/j.peptides.2007.06.022
1990, J Biol Chem, 265, 17364, 10.1016/S0021-9258(17)44911-8
1992, Am J Physiol, 263, G901, 10.1152/ajpcell.1992.263.4.C901
2000, J Neurosci, 20, 3596, 10.1523/JNEUROSCI.20-10-03596.2000
1998, Am J Physiol, 274, E834
10.1016/S0167-0115(98)00037-8
1992, Lab Invest, 67, 387
10.1016/S1074-7613(01)00198-4
10.1016/0196-9781(95)00087-Z
10.1097/00001756-200104170-00011
10.1016/0306-4522(94)00522-7
1994, J Biol Chem, 269, 6207, 10.1016/S0021-9258(17)37589-0
10.1002/(SICI)1097-0215(19990412)81:2<165::AID-IJC1>3.0.CO;2-0
10.1016/j.peptides.2007.06.012
10.1016/S0304-3940(98)00041-X
2001, Am J Physiol Regul Integr Comp Physiol, 281, R1562, 10.1152/ajpregu.2001.281.5.R1562
10.1016/S0014-2999(02)01275-X
2001, Am J Physiol Regul Integr Comp Physiol, 281, R495, 10.1152/ajpregu.2001.281.2.R495
10.1016/0898-6568(94)90037-X
10.1016/j.ygcen.2009.05.003
10.1016/S0960-5428(96)00007-1
10.1177/154411130201300303
10.1016/j.canlet.2003.10.008
10.1080/09513590500098240
10.1016/S0196-9781(03)00162-1
1994, Br J Pharmacol, 111, 589, 10.1111/j.1476-5381.1994.tb14778.x
10.1016/S0143-4179(96)90042-6
1997, Am J Physiol, 272, R1606
10.1016/j.peptides.2005.06.022
1997, Am J Physiol, 273, R1339
MJ Eiden, LE (2007) Regulation of PC12 cell differentiation by cAMP signaling to ERK independent of PKA: do all the connections add up?Sci STKE 2007:pe 15.
1998, Mol Brain Res, 61, 207, 10.1016/S0169-328X(98)00202-2
10.1007/s00441-002-0576-1
1999, Recent Prog Horm Res, 54, 33
Goetzl, EJ , Voice, JK, Shen, S, Dorsam, G, Kong, Y, West, KM, Morrison, CF Harmar, AJ (2001) Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor forvasoactive intestinal peptide.Proc Natl Acad Sci U S A 98:13854–13859.
1998, J Neuropathol Exp Neurol, 57, 991, 10.1097/00005072-199811000-00001
1996, Ann N Y Acad Sci, 805, 302
10.1016/S0306-4522(96)00617-3
1998, Ann Endocrinol, 59, 364
1994, Ann Endocrinol), 55, 24
10.1016/S0968-0896(01)00190-0
10.2174/138161207780618966
1979, Mol Cell Biochem, 25, 79
1991, FASEB J, 5, 194, 10.1096/fasebj.5.2.1848519
10.1016/0006-8993(94)91233-5
10.1016/S0196-9781(97)00230-1
1991, Biochim Biophys Acta, 1066, 245, 10.1016/0005-2736(91)90193-C
10.1111/j.1749-6632.1998.tb11184.x
1996, Int J Pept Protein Res, 48, 391, 10.1111/j.1399-3011.1996.tb00856.x
10.1016/0014-2999(95)00467-5
10.1016/0167-0115(96)00010-9
10.1016/S0196-9781(97)00228-3
10.1016/S0196-9781(96)00322-1
1991, Eur J Biochem, 195, 535, 10.1111/j.1432-1033.1991.tb15734.x
10.1111/j.1471-4159.2008.05231.x
Gozes, I , Perl, O, Giladi, E, Davidson, A, Ashur-Fabian, O, Rubinraut, S Fridkin, M (1999)96:Proc Natl Acad Sci U S A4143–4148.
10.1016/0167-0115(94)00116-F
10.1016/j.regpep.2004.12.021
10.1016/j.peptides.2006.04.008
10.1007/s11064-005-8807-y
1999, J Pharmacol Exp Ther, 288, 1207
1998, J Neurochem, 70, 2574, 10.1046/j.1471-4159.1998.70062574.x
10.1046/j.1460-9568.1998.00172.x
10.1016/0165-1838(94)90005-1
10.1046/j.1460-9568.1999.00693.x
10.1016/S0006-8993(97)01011-1
10.1046/j.1460-9568.2003.02426.x
10.1016/0303-7207(81)90052-6
10.1016/S0167-0115(02)00107-6
10.1016/j.regpep.2006.04.023
2003, J Neurosci, 23, 2274, 10.1523/JNEUROSCI.23-06-02274.2003
10.1113/jphysiol.1994.sp020092
1987, Am J Physiol, 253, G298
10.1016/S0169-328X(00)00070-X
10.1152/ajpcell.00495.2005
10.1016/j.ejphar.2008.05.045
10.1016/S0196-9781(98)00115-6
1998, Yale J Biol Med, 71, 163
2002, J Neurosci, 22, 5310, 10.1523/JNEUROSCI.22-13-05310.2002
Hamelink, C , Tjurmina, O, Damadzic, R, Young, WS, Weihe, E, Lee, HW Eiden, LE (2002b)99:Proc Natl Acad Sci U S A461–466.
10.1046/j.1365-2826.1996.04747.x
1998, Microbiol Mol Biol Rev, 62, 465, 10.1128/MMBR.62.2.465-503.1998
10.1016/0167-0115(94)00110-J
10.1152/ajpregu.90563.2008
1997, J Neurosci, 17, 2637, 10.1523/JNEUROSCI.17-07-02637.1997
2001, J Neurosci, 21, 4883, 10.1523/JNEUROSCI.21-13-04883.2001
10.1016/0167-0115(94)00099-J
10.1177/074873001129002132
10.1097/WNR.0b013e32832ca201
10.1111/j.1749-6632.1998.tb11197.x
1998, Pharmacol Rev, 50, 265
10.1016/S0092-8674(02)00736-5
1999, J Neurosci, 19, 6637, 10.1523/JNEUROSCI.19-15-06637.1999
1998, J Neurochem, 71, 161, 10.1046/j.1471-4159.1998.71010161.x
10.1046/j.1471-4159.2000.740501.x
10.1016/0896-6273(93)90188-W
10.1016/j.bbrc.2003.10.005
10.1002/(SICI)1096-9861(19960805)371:4<567::AID-CNE6>3.0.CO;2-2
10.1016/S0006-291X(02)02144-7
10.1046/j.1471-4159.2000.0751810.x
Hashimoto, H , Shintani, N, Tanaka, K, Mori, W, Hirose, M, Matsuda, T, Sakaue, M, Miyazaki, J, Niwa, H, Tashiro, F, et al.(2001)98:Proc Natl Acad Sci U S A13355–13360.
1996, Biochim Biophys Acta, 1281, 129, 10.1016/0005-2736(96)00056-9
10.1016/0739-7240(94)90004-3
1992, Acta Otolaryngol, 112, 343, 10.1080/00016489.1992.11665430
10.1016/0167-0115(96)00100-0
10.2209/tdcpublication.43.31
10.1016/S0196-9781(98)00051-5
1995, Br J Pharmacol, 116, 2258, 10.1111/j.1476-5381.1995.tb15062.x
1994, Acta Physiol Scand, 150, 103, 10.1111/j.1748-1716.1994.tb09665.x
10.1095/biolreprod47.5.800
10.1095/biolreprod54.3.523
10.1016/j.peptides.2007.12.009
10.1016/0950-3528(93)90029-R
10.1016/0196-9781(95)00059-S
1995, Arzneimittelforschung, 45, 689
10.1016/0006-291X(85)91917-5
10.1111/j.1440-1681.2003.03940.x
2007, Am J Physiol Heart Circ Physiol, 292, 1861, 10.1152/ajpheart.00826.2006
10.1016/S0014-2999(98)00210-6
1997, J Pharmacol Exp Ther, 283, 478
10.1016/S0014-2999(97)01312-5
10.1097/00005344-199702000-00010
10.1016/j.regpep.2004.08.018
10.1016/S1359-6446(05)03370-2
1996, Neuroreport, 8, 297, 10.1097/00001756-199612200-00059
10.1016/j.regpep.2004.05.018
10.1111/j.1749-6632.1998.tb11220.x
Hoover, DB , Tompkins, JD Parsons, RL (2009) ifferential activation of Guinea-pig intrinsic cardiac neurons by the PAC1 agonists maxadilan and PACAP27. J Pharmacol Exp Therdoi: 10.1124/jpet.109.155747
10.1016/0304-3940(93)90792-J
1992, Biochim Biophys Acta, 1129, 199, 10.1016/0167-4781(92)90488-L
10.1016/S0028-3908(05)80009-7
1994, Jpn J Pharmacol, 66, 323, 10.1254/jjp.66.323
10.1016/0024-3205(95)00154-X
10.1016/S0167-0115(97)01073-2
10.1016/0196-9781(87)90013-1
10.1016/0196-9781(93)90109-T
1972, Gastroenterology, 62, 318, 10.1016/S0016-5085(72)80186-0
1989, Biochem Int, 19, 951
10.1523/JNEUROSCI.5345-03.2004
10.1016/S0196-9781(97)00123-X
10.1002/(SICI)1097-4547(19980201)51:3<382::AID-JNR11>3.0.CO;2-9
10.1016/S0168-0102(03)00165-2
1992, Int J Pept Protein Res, 40, 456, 10.1111/j.1399-3011.1992.tb00324.x
10.1016/j.mce.2007.09.003
10.1016/j.regpep.2004.05.020
10.1016/0896-6273(92)90101-I
10.1016/0306-4522(95)00038-K
10.1016/0167-0115(92)90081-5
10.1016/j.regpep.2004.05.011
10.1016/0143-4179(94)90107-4
1996, Ann N Y Acad Sci, 805, 464
10.1016/S0167-0115(98)00135-9
10.1016/S0168-0102(99)00097-8
Iwanij, V Hur, KC (1985)82:Proc Natl Acad Sci U S A325–329.
10.1016/j.jbbm.2004.03.002
10.1046/j.1471-4159.2002.01124.x
2000, Ann N Y Acad Sci, 921, 400, 10.1111/j.1749-6632.2000.tb07004.x
10.1016/0165-1838(94)90095-7
10.1016/0024-3205(92)90609-S
10.1016/S0165-3806(99)00192-3
10.1002/(SICI)1096-9861(19990920)412:2<218::AID-CNE3>3.0.CO;2-L
1997, Cancer Res, 57, 1475
10.1016/S0165-5728(02)00365-X
10.1016/0165-5728(96)00085-9
10.1016/j.neuroscience.2009.02.028
10.1016/S0006-8993(99)02233-7
10.1097/00001756-200107200-00034
10.1002/(SICI)1097-4547(20000315)59:6<760::AID-JNR8>3.0.CO;2-7
2007, Pharmacol Rep, 59, 414
10.1016/S0898-6568(01)00199-1
10.1002/(SICI)1097-0045(19990915)41:1<1::AID-PROS1>3.0.CO;2-A
10.1016/0024-3205(95)02143-7
10.1016/j.autneu.2004.01.002
2003, Clin Invest Med, 26, 285
1993, Res Commun Chem Pathol Pharmacol, 79, 11
10.1016/j.mce.2004.09.004
10.1016/S0167-0115(02)00192-1
10.1002/(SICI)1097-4652(199607)168:1<141::AID-JCP17>3.0.CO;2-A
1993, Tohoku J Exp Med, 171, 243, 10.1620/tjem.171.243
1991, Tohoku J Exp Med, 164, 309, 10.1620/tjem.164.309
1995, Agents Actions Suppl, 45, 283
1993, Am J Physiol, 265, G295
10.1016/0196-9781(93)90149-B
1996, J Pharmacol Exp Ther, 278, 199
10.1016/j.bbrc.2003.09.004
10.1016/0024-3205(92)90332-J
10.1016/0026-0495(94)90124-4
10.1016/S0169-328X(01)00241-8
10.1016/j.neuron.2004.10.006
10.1016/j.peptides.2007.03.013
10.1016/S0039-6060(96)80077-8
10.1016/0006-291X(90)91914-E
10.1016/0006-8993(87)90330-1
10.1097/00005537-200306000-00016
10.1111/j.1365-2826.1994.tb00612.x
10.1046/j.1365-2222.2003.01721.x
10.1016/S0196-9781(02)00149-3
10.1016/S0196-9781(01)00568-X
10.1016/j.ygcen.2006.12.012
1995, Biomed Pept Proteins Nucleic Acids, 1, 73
10.1016/0891-0618(92)90036-P
10.1097/00001756-199611040-00078
10.1016/0006-8993(94)91409-5
10.1016/0167-0115(92)90071-2
10.1016/0303-7207(92)90235-X
10.1016/0303-7207(93)90005-5
10.1016/0303-7207(95)03583-S
Koh, JY , Palmer, E Cotman, CW (1991)88:Proc Natl Acad Sci U S A9431–9435.
2005, J Vet Sci, 6, 1, 10.4142/jvs.2005.6.1.1
10.1111/j.1439-0388.2006.00621.x
1996, Mol Pharmacol, 50, 1047
1998, J Neurosci, 18, 1478, 10.1523/JNEUROSCI.18-04-01478.1998
10.1016/S0306-4522(98)00606-X
2004, J Physiol Pharmacol, 55, 5
10.1016/S0304-3940(97)00312-1
1999, J Neurosci, 19, 206, 10.1523/JNEUROSCI.19-01-00206.1999
10.1016/S0196-9781(97)00019-3
10.1016/S0196-9781(97)00142-3
1997, Thyroid, 7, 943, 10.1089/thy.1997.7.943
10.1016/0196-9781(93)90131-Y
1994, Acta Biol Hung, 45, 297
10.1016/S0196-9781(98)00049-7
1995, Horm Metab Res, 27, 110, 10.1055/s-2007-979920
10.1016/S0006-8993(97)00737-3
10.1016/0143-4179(95)90001-2
1998, Histol Histopathol, 13, 373
1993, Am J Physiol, 264, G433
10.1016/S0167-0115(02)00099-X
Laburthe, M , Couvineau, A Nicole, PVaudry, H, Arimura, A & Melmed, S (2003) Molecular pharmacology and structure-function analysis of PACAP/VIP receptors,inPituitary Adenylate Cyclase-Activating PolypeptideKluwer Academic Publishers, Amsterdam.69–94.
10.1016/j.peptides.2007.04.026
1996, Ann N Y Acad Sci, 805, 94
Lacombe, A , Lelievre, V, Roselli, CE, Salameh, W, Lue, YH, Lawson, G, Muller, JM, Waschek, JA Vilain, E (2006)103:Proc Natl Acad Sci U S A3793–3798.
1990, Eur J Biochem, 193, 725, 10.1111/j.1432-1033.1990.tb19392.x
2001, Am J Physiol Regul Integr Comp Physiol, 280, R510, 10.1152/ajpregu.2001.280.2.R510
2003, Am J Physiol Regul Integr Comp Physiol, 284, R588, 10.1152/ajpregu.00466.2002
1999, Am J Physiol, 276, R162
1991, Mol Brain Res, 9, 217, 10.1016/0169-328X(91)90005-I
Lang, B , Zhao, L, Cai, L, McKie, L, Forrester, JV, McCaig, CD, Jackson, IJ Shen, S (2009) ABAergic amacrine cells and visual function are reduced in PAC1 transgenic mice. Neuropharmacologydoi: 10.1016/j.neuropharm.2009.07.003
10.1111/j.1365-2826.1995.tb00811.x
10.1016/j.mcn.2008.07.009
10.1016/S0167-0115(99)00024-5
10.1016/S0016-5085(99)70184-8
10.1097/01.wnr.0000130541.29635.6f
10.1046/j.1471-4159.1999.731769.x
Lee, LT , Siu, FK, Tam, JK, Lau, IT, Wong, AO, Lin, MC, Vaudry, H Chow, BK (2007)104:Proc Natl Acad Sci U S A2133–2138.
10.1111/j.1749-6632.2008.03661.x
10.1016/S0016-5085(98)70326-9
2007, Neural Plast, 2007, 79102
10.1016/S0304-3940(98)00255-9
10.1016/0304-3940(94)90080-9
10.1016/S0143-4179(96)90019-0
Lelièvre, V , Meunier, AC, Caigneaux, E, Falcon, J Muller, JM(1998a)Differential expression and function of PACAP and VIP receptors in four human colonic adenocarcinoma cell lines. Cell Signal 10: 13–26.
Lelièvre, V , Pineau, N Waschek, JAVaudry, H, Arimura, A & Melmed, S (2003) The biological significance of PACAP and PACAP receptors in human tumors: from cell lines to cancersPituitary Adenylate Cyclase-Activating PolypeptideKluwer Academic Publishers,Amsterdam.361–400,
10.1016/j.ydbio.2007.10.031
10.1016/j.brainres.2007.06.032
10.1016/j.brainres.2009.06.021
1992, Neuro Endocrinol Lett, 14, 319
10.1016/j.peptides.2007.06.021
1991, J Biol Chem, 266, 11234, 10.1016/S0021-9258(18)99153-2
10.1183/09031936.00050008
10.1016/S0304-3835(97)00525-9
1999, Breast Cancer Res Treat, 56, 177
10.1016/j.peptides.2007.05.002
10.1016/j.regpep.2007.09.012
2000, Ann N Y Acad Sci, 921, 333, 10.1111/j.1749-6632.2000.tb06988.x
10.1016/S0196-9781(97)00293-3
Li, P , Chang, TM, Coy, D Chey, WY(2000c)Inhibition of gastric acid secretion in rat stomach by PACAP is mediated by secretin, somatostatin, and PGE(2). Am J Physiol 278: G121–127.
1996, Mol Brain Res, 41, 157, 10.1016/0169-328X(96)00086-1
1994, J Mol Neurosci, 5, 231, 10.1007/BF02736724
10.1034/j.1399-3003.1999.14b34.x
10.1016/S0196-9781(97)00017-X
1995, Br J Pharmacol, 115, 913, 10.1111/j.1476-5381.1995.tb15897.x
10.1111/j.1749-6632.1998.tb11178.x
10.1016/S0167-0115(97)01018-5
10.1111/j.1469-7793.2001.00663.x
10.1002/(SICI)1097-4547(19980115)51:2<243::AID-JNR13>3.0.CO;2-9
1999, J Androl, 20, 366, 10.1002/j.1939-4640.1999.tb02530.x
10.1046/j.1460-9568.2000.00116.x
1997, J Neurophysiol, 78, 2231, 10.1152/jn.1997.78.4.2231
10.1016/S0006-8993(97)01567-9
10.1016/j.bbrc.2008.05.119
Lu, N DiCicco-Bloom, E (1997)94:Proc Natl Acad Sci U S A3357–3362.
10.1002/(SICI)1097-4547(19980915)53:6<651::AID-JNR3>3.0.CO;2-4
10.1016/S8756-3282(00)00394-X
10.1016/0167-0115(94)90030-2
10.1016/j.mcn.2005.09.008
10.1016/S0014-5793(99)01135-7
10.1016/0014-5793(93)81668-P
1996, Neuroendocrinology, 64, 153, 10.1159/000127113
10.1523/JNEUROSCI.0983-04.2004
10.1523/JNEUROSCI.3871-05.2005
2007, Biochim Biophys Acta, 1768, 941, 10.1016/j.bbamem.2006.12.006
1996, Genomics, 37, 345, 10.1006/geno.1996.0569
1998, Cancer Res, 58, 4845
10.1111/j.1749-6632.1998.tb11181.x
10.1016/0167-0115(88)90022-5
1979, J Biol Chem, 254, 7885, 10.1016/S0021-9258(18)36029-0
1998, Am J Physiol, 274, G217
10.1016/0165-1838(96)00044-6
10.1016/S0248-4900(98)80006-3
10.1016/0306-4522(87)90075-3
10.1016/0006-8993(92)91423-C
10.1046/j.1471-4159.1995.65010001.x
10.1016/S0169-328X(02)00646-0
Martínez, C , Abad, C, Delgado, M, Arranz, A, Juarranz, MG, Rodriguez-Henche, N, Brabet, P, Leceta, J Gomariz, RP (2002)99:Proc Natl Acad Sci U S A1053–1058.
1996, J Immunol, 156, 4128, 10.4049/jimmunol.156.11.4128
Martínez, C , Delgado, M, Pozo, D, Leceta, J, Calvo, JR, Ganea, D Gomariz, RP(1998a)Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J Leukoc Biol 63: 591–601.
10.1016/S0165-5728(98)00018-6
Martínez-Fuentes, AJ , Castaño, JP, Gracia-Navarro, F Malagón, MM(1998a)Pituitary adenylate cyclase-activating polypeptide (PACAP) 38 and PACAP27 activate common and distinct intracellular signaling pathways to stimulate growth hormone secretion from porcine somatotropes. Endocrinology 139: 5116–5124.
Martínez-Fuentes, AJ , Castaño, JP, Malagón, MM, Vázquez-Martínez, R Gracia-Navarro, F(1998b)Pituitary adenylate cyclase-activating polypeptides 38 and 27 increase cytosolic free Ca2+ concentration in porcine somatotropes through common and distinct mechanisms. Cell Calcium 23: 369–378.
Martinez-Fuentes, AJ , Gonzalez de Aguilar, JL, Lacuisse, S, Kihuyama, S, Vaudry, H Gracia-Navarro, FRosselin, G (1994) Effect of frog pituitary adenylate cyclase-activating polypeptide (PACAP) on amphibian pituitary cells, inVasoactive Intestinal Peptide, Pituitary Adenylate Cyclase-Activating Polypeptide and Related PeptidesWorld Scientific,London.376–380.
Martínez-Fuentes, AJ , Malagón, MM, Castaño, JP, Garrido-Gracia, JC Gracia-Navarro, F(1998c)Pituitary adenylate cyclase-activating polypeptide (PACAP) 38 and PACAP27 differentially stimulate growth hormone release and mRNA accumulation in porcine somatotropes. Life Sci 62: 2379–2390.
10.1016/j.peptides.2007.05.015
10.1016/0143-4160(95)90067-5
10.1016/0006-8993(95)00978-Y
10.1016/0304-3940(91)90529-3
10.1016/0006-8993(92)90430-H
10.1016/0006-8993(93)90241-E
10.1016/0304-3940(94)90234-8
10.1016/j.devbrainres.2004.05.003
10.1016/j.peptides.2007.03.007
10.1016/j.peptides.2005.02.022
10.1016/j.regpep.2004.08.019
10.1016/j.regpep.2007.08.018
10.1016/S0196-9781(97)00122-8
10.1111/j.1365-2982.2004.00574.x
10.1016/S0196-9781(00)00215-1
10.1016/j.regpep.2007.08.016
10.1517/14728222.12.9.1097
10.1016/j.cub.2006.02.023
1997, Horm Metab Res, 29, 86, 10.1055/s-2007-978993
10.1016/1043-2760(96)00051-3
10.1016/0378-1119(94)00856-N
10.1016/0303-7207(94)03467-8
10.1111/j.1460-9568.2004.03227.x
10.1016/j.regpep.2004.04.019
1996, Ann N Y Acad Sci, 805, 443
2002, Regul Pept, 105, 145, 10.1016/S0167-0115(02)00003-4
10.1111/j.1365-2826.1995.tb00666.x
10.1016/0304-3940(94)90620-3
10.1016/S0306-4522(02)00148-3
Minkes, RK , McMahon, TJ, Higuera, TR, Murphy, WA, Coy, DH Kadowitz, PJ(1992a)Analysis of systemic and pulmonary vascular responses to PACAP and VIP: role of adrenal catecholamines. Am J Physiol 263: 1659–1669.
Minkes, RK , McMahon, TJ, Hood, JS, Murphy, WA, Coy, DH, McNamara, DB Kadowitz, PJ(1992b)Differential effects of PACAP and VIP on the pulmonary and hindquarters vascular beds of the cat. J Appl Physiol 72: 1212–1217.
1997, Acta Physiol Scand, 160, 15, 10.1046/j.1365-201X.1997.00010.x
10.1016/j.ygcen.2007.05.007
1994, Biochim Biophys Acta, 1218, 297, 10.1016/0167-4781(94)90181-3
10.1016/0006-291X(89)91757-9
10.1016/0006-291X(90)92140-U
10.1111/j.1749-6632.1998.tb11165.x
10.1046/j.1365-2826.1998.00244.x
10.1016/0167-0115(96)00033-X
10.1016/S0006-8993(97)00923-2
10.1016/S0006-8993(97)00937-2
10.1016/0306-4522(93)90018-B
Monaghan, TK , Mackenzie, CJ, Plevin, R Lutz, EM(2008a)PACAP-38 induces neuronal differentiation of human SH-SY5Y neuroblastoma cells via cAMP-mediated activation of ERK and p38 MAP kinases. J Neurochem 104: 74–88.
Monaghan, TK , Pou, C, MacKenzie, CJ, Plevin, R Lutz, EM(2008b)Neurotrophic actions of PACAP-38 and LIF on human neuroblastoma SH-SY5Y cells. J Mol Neurosci 36: 45–56.
1998, DNA Cell Biol, 17, 151, 10.1089/dna.1998.17.151
10.1016/S0024-3205(97)00771-6
10.1016/S0196-9781(97)00459-2
10.1016/0196-9781(93)90036-G
Moore, JP, Jr, Villafuerte, BC, Unick, CA Winters, SJ (2009) Developmental changes in pituitary PACAP expression during the perinatal period: possible role in fetal gonadotroph regulation. Endocrinologydoi: 10.1210/en.2008-1649
10.1016/S0196-9781(00)00309-0
10.1016/S0006-8993(96)00920-1
10.1016/0898-6568(94)00081-L
10.1016/0196-9781(92)90019-Y
10.1016/S0006-8993(98)00291-1
10.1016/0014-5793(93)80202-6
Mounien, L , Bizet, P, Boutelet, I, Gourcerol, G, Basille, M, Gonzalez, B, Vaudry, H Jegou, S(2006a)Expression of PACAP receptor mRNAs by neuropeptide Y neurons in the rat arcuate nucleus. Ann N Y Acad Sci 1070: 457–461.
Mounien, L , Bizet, P, Boutelet, I, Gourcerol, G, Fournier, A, Vaudry, H Jégou, S(2006b)Pituitary adenylate cyclase-activating polypeptide directly modulates the activity of proopiomelanocortin neurons in the rat arcuate nucleus. Neuroscience 143: 155–163.
10.1016/j.regpep.2005.09.019
10.1016/0167-0115(95)00082-M
10.1016/0306-4522(94)90025-6
Mungan, Z , Arimura, A, Ertan, A, Rossowski, WJ Coy, DH(1992a)Pituitary adenylate cyclase-activating polypeptide relaxes rat gastrointestinal smooth muscle. Scand J Gastroenterol 27: 375–380.
10.1016/0196-9781(91)90101-T
10.1016/0196-9781(95)00083-V
Mungan, Z , Ozmen, V, Ertan, A Arimura, A(1992b)Pituitary adenylate cyclase activating polypeptide-27 (PACAP-27) inhibits pentagastrin-stimulated gastric acid secretion in conscious rats. Regul Pept 38: 199–206.
10.1016/0167-0115(95)00003-T
10.1016/0304-3940(94)11235-B
1993, Neuroendocrinology, 57, 1092, 10.1159/000126475
1994, Horm Res, 42, 257, 10.1159/000184205
1997, Am J Physiol, 272, G1391
10.1016/0014-5793(95)00214-T
10.1016/j.peptides.2007.07.013
10.1016/S0006-8993(02)02538-6
10.1016/j.peptides.2006.01.007
10.1016/j.neulet.2004.08.034
10.1016/j.peptides.2005.12.011
10.1097/00006676-199209000-00006
10.1016/0196-9781(93)90139-8
10.1016/S0303-7207(01)00402-6
1993, Am J Physiol, 265, G811
Nicot, A DiCicco-Bloom, E (2001)98:Proc Natl Acad Sci U S A4758–4763.
2002, J Neurosci, 22, 9244, 10.1523/JNEUROSCI.22-21-09244.2002
10.1523/JNEUROSCI.1910-04.2004
10.1016/S0169-328X(02)00395-9
10.1002/(SICI)1096-9861(19980518)394:4<403::AID-CNE1>3.0.CO;2-5
1998, Neuroreport, 9, 2639, 10.1097/00001756-199808030-00039
10.1016/j.mcn.2003.12.004
10.1007/s12031-008-9085-3
2002, Pol J Pharmacol, 54, 717, 10.1211/0022357021778871
10.1016/0014-2999(94)90752-8
10.1016/0014-5793(85)80953-4
1997, Jpn J Pharmacol, 75, 203, 10.1254/jjp.75.203
Nogi, H , Hashimoto, H, Hagihara, N, Shimada, S, Yamamoto, K, Matsuda, T, Tohyama, M Baba, A(1997b)Distribution of mRNAs for pituitary adenylate cyclase-activating polypeptide (PACAP), PACAP receptor, vasoactive intestinal polypeptide (VIP), and VIP receptors in the rat superior cervical ganglion. Neurosci Lett 227: 37–40.
10.1097/00001756-199612200-00014
10.1016/j.expneurol.2004.09.013
10.1016/j.regpep.2004.12.023
10.1016/j.peptides.2007.04.007
10.1016/S0006-8993(99)01367-0
10.1016/S0196-9781(98)00102-8
10.1111/j.1476-5381.1995.tb15939.x
10.1016/0167-0115(92)90616-3
10.1111/j.1471-4159.2006.04390.x
10.1016/S0304-3835(97)00510-7
10.1016/S0006-291X(05)80924-6
1992, DNA Cell Biol, 11, 21, 10.1089/dna.1992.11.21
10.1016/j.regpep.2004.08.028
10.1016/j.regpep.2004.05.013
Ohtaki, H , Nakamachi, T, Dohi, K, Aizawa, Y, Takaki, A, Hodoyama, K, Yofu, S, Hashimoto, H, Shintani, N, Baba, A, et al.(2006)103:Proc Natl Acad Sci U S A7488–7493.
1993, J Biol Chem, 268, 26650, 10.1016/S0021-9258(19)74361-0
10.1016/0006-291X(90)91222-E
10.1016/j.bbrc.2008.03.028
1999, Am J Pathol, 155, 1893, 10.1016/S0002-9440(10)65509-5
10.1016/S0002-9440(10)65693-3
10.1111/j.1749-6632.2008.03662.x
10.1016/j.peptides.2007.03.012
10.1016/0196-9781(95)02018-R
10.1016/0014-5793(92)80020-H
1996, Ann N Y Acad Sci, 805, 595
10.1046/j.1365-2826.1997.00663.x
1997, J Neurochem, 69, 1213, 10.1046/j.1471-4159.1997.69031213.x
1994, Cell Tissue Res, 277, 539, 10.1007/BF00300227
2000, J Exp Biol, 203, 575, 10.1242/jeb.203.3.575
2001, Comp Biochem Physiol A Mol Integr Physiol, 128, 481
10.1016/S0167-0115(97)01055-0
10.1016/S0742-8413(96)00078-3
Onoue, S , Endo, K, Ohshima, K, Yajima, T Kashimoto, K(2002a)The neuropeptide PACAP attenuates beta-amyloid (1–42)-induced toxicity in PC12 cells. Peptides 23: 1471–1478.
Onoue, S , Endo, K, Yajima, T Kashimoto, K(2002b)Pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide attenuate glutamate-induced nNOS activation and cytotoxicity. Regul Pept 107: 43–47.
2008, FEBS J, 275, 5542, 10.1111/j.1742-4658.2008.06672.x
2004, Eur J Biochem, 271, 1757, 10.1111/j.1432-1033.2004.04086.x
Onoue, S , Ohshima, K, Endo, K, Yajima, T Kashimoto, K(2002c)PACAP protects neuronal PC12 cells from the cytotoxicity of human prion protein fragment 106–126. FEBS Lett 522: 65–70.
10.1016/S0196-9781(01)00411-9
Onyüksel, H , Jeon, E Rubinstein, I(2009a)Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells. Cancer Lett 274: 327–330.
Onyüksel, H , Mohanty, PS Rubinstein, I(2009b)VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer. Int J Pharm 365: 157–161.
10.1507/endocrj1954.39.153
10.1161/01.CIR.0000147235.53360.59
Otto, C , Kovalchuk, Y, Wolfer, DP, Gass, P, Martin, M, Zuschratter, W, Gröne, HJ, Kellendonk, C, Tronche, F, Maldonado, R, et al.(2001a)Impairment of mossy fiber long-term potentiation and associative learning in pituitary adenylate cyclase activating polypeptide type I receptor-deficient mice. J Neurosci 21: 5520–5527.
Otto, C , Martin, M, Wolfer, DP, Lipp, HP, Maldonado, R Schütz, G(2001b)Altered emotional behavior in PACAP-type-I-receptor-deficient mice. Mol Brain Res 92: 78–84.
1999, Mol Brain Res, 66, 163, 10.1016/S0169-328X(99)00010-8
10.1016/0006-8993(95)00869-R
1999, Mol Cells, 9, 146, 10.1016/S1016-8478(23)13522-9
1993, Eur J Biochem, 215, 439, 10.1111/j.1432-1033.1993.tb18051.x
2000, Ann N Y Acad Sci, 921, 202, 10.1111/j.1749-6632.2000.tb06967.x
10.1111/j.1749-6632.1998.tb10818.x
1999, Mol Brain Res, 71, 244, 10.1016/S0169-328X(99)00197-7
10.1016/S0167-0115(97)01012-4
10.1046/j.1460-9568.1998.00052.x
10.1016/0022-3468(92)90536-G
10.1001/archsurg.1993.01420170127020
10.1111/j.1460-9568.2004.03845.x
1995, Exp Clin Endocrinol Diabetes, 103, 81
1993, Exp Clin Endocrinol, 101, 290
10.1016/j.bbrc.2005.07.135
10.1046/j.1365-201X.2002.00977.x
2005, Acta Orthop, 76, 465, 10.1080/17453670510041420
10.1016/j.npep.2006.04.001
1996, Exp Clin Endocrinol Diabetes, 104, 250
10.1097/00006676-200107000-00010
10.1016/S0304-3940(01)01796-7
10.1002/(SICI)1096-9861(19961209)376:2<278::AID-CNE9>3.0.CO;2-0
10.1016/j.peptides.2006.06.007
Pisegna, JR Wank, SA (1993)90:Proc Natl Acad Sci U S A6345–6349.
1996, Ann N Y Acad Sci, 805, 54
10.1016/S0167-0115(02)00295-1
1997, Biochim Biophys Acta, 1359, 250, 10.1016/S0167-4889(97)00104-3
10.1146/annurev.physiol.65.092101.142205
10.1016/0006-8993(95)00824-A
10.1016/j.ygcen.2006.12.006
10.1016/j.regpep.2007.09.015
10.1007/s12031-008-9112-4
1998, J Nucl Med, 39, 1570
1996, Scand J Urol Nephrol Suppl, 179, 81
1997, J Pharmacol Exp Ther, 283, 722
10.1016/0167-0115(91)90200-Z
Ravni, A , Bourgault, S, Lebon, A, Chan, P, Galas, L, Fournier, A, Vaudry, H, Gonzalez, B, Eiden, LE Vaudry, D(2006a)The neurotrophic effects of PACAP in PC12 cells: control by multiple transduction pathways. J Neurochem 98: 321–329.
Ravni, A , Eiden, LE, Vaudry, H, Gonzalez, BJ Vaudry, D(2006b)Cycloheximide treatment to identify components of the transitional transcriptome in PACAP-induced PC12 cell differentiation. J Neurochem 98: 1229–1241.
10.1016/0303-7207(94)90212-7
10.1016/S1043-2760(96)00187-7
1994, J Biol Chem, 269, 5680, 10.1016/S0021-9258(17)37514-2
10.1016/0006-291X(91)91351-C
10.1046/j.1365-2826.2002.00826.x
10.1016/S0166-4328(02)00289-9
10.1016/j.npep.2006.06.001
10.1016/j.bbr.2003.09.007
10.1016/S0196-9781(02)00262-0
10.1016/S0739-7240(98)00027-7
1995, J Nucl Med, 36, 1846
10.1111/j.1749-6632.2000.tb06343.x
Reubi, JC , Waser, B, Schmassmann, A Laissue, JA(1999a)Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin and vasoactive intestinal peptide receptors in gastro-intestinal adenocarcinoma samples: where are they really located?Int J Cancer 81: 376–386.
Reubi, JC , Zimmermann, A, Jonas, S, Waser, B, Neuhaus, P, Läderach, U Wiedenmann, B(1999b)Regulatory peptide receptors in human hepatocellular carcinomas. Gut 45: 766–774.
10.1016/S0006-8993(97)01231-6
1995, Recent Prog Horm Res, 50, 223
10.1007/s00441-003-0805-2
10.1016/0024-3205(94)00614-8
10.1016/S0014-2999(98)00662-1
Robberecht, P , Gourlet, P, Cauvin, A, Buscail, L, De Neef, P, Arimura, A Christophe, J(1991a)PACAP and VIP receptors in rat liver membranes. Am J Physiol 260: G97–102.
Robberecht, P , Gourlet, P, De Neef, P, Woussen-Colle, MC, Vandermeers-Piret, MC, Vandermeers, A Christophe, J(1992a)Receptor occupancy and adenylate cyclase activation in AR 4–2J rat pancreatic acinar cell membranes by analogs of pituitary adenylate cyclase-activating peptides amino-terminally shortened or modified at position 1, 2, 3, 20, or 21. Mol Pharmacol 42: 347–355.
1992, Eur J Biochem, 207, 239, 10.1111/j.1432-1033.1992.tb17043.x
Robberecht, P , Vertongen, P, Langer, I Perret, JVaudry, H, Arimura, A & Melmed, S (2003) Development of selective ligands for PAC1, VPAC1 and VPAC2 receptors, in Pituitary Adenylate Cyclase-Activating PolypeptideKluwer Academic Publishers,Amsterdam.49–67,
10.1016/0196-9781(84)90110-4
10.1016/0014-5793(88)80030-9
1982, Digestion, 23, 201, 10.1159/000198728
Robberecht, P , Woussen-Colle, MC, De Neef, P, Gourlet, P, Buscail, L, Vandermeers, A, Vandermeers-Piret, MC Christophe, J(1991b)The two forms of the pituitary adenylate cyclase activating polypeptide (PACAP (1–38)) interact with distinct receptors on rat pancreatic AR 4–2J cell membranes. FEBS Lett 286: 133–136.
10.1016/0196-9781(94)90092-2
10.1016/S0167-4781(02)00303-2
1995, Rev Esp Fisiol, 51, 29
10.1016/S0143-4179(97)90064-0
1993, Pediatr Res, 34, 323, 10.1203/00006450-199309000-00017
10.1016/0303-7207(82)90092-2
10.1016/0196-9781(85)90071-3
10.1111/j.1749-6632.2008.03635.x
10.1046/j.1365-2826.1999.00334.x
10.1007/978-3-642-45525-4_15
10.1016/j.cbi.2007.03.008
10.1016/0167-0115(95)00131-X
1998, J Neurosci, 18, 6662, 10.1523/JNEUROSCI.18-17-06662.1998
2000, Trends Pharmacol Sci, 21, 57
2004, Mol Brain Res, 123, 18, 10.1016/j.molbrainres.2003.12.013
1994, Am J Physiol, 267, 256
Sakuma, Y , Ricordi, C, Miki, A, Yamamoto, T, Mita, A, Barker, S, Damaris, RM, Pileggi, A, Yasuda, Y, Yada, T, et al.(2009)41:Transplant Proc343–345.
1993, Am J Physiol, 264, E294
10.1016/j.peptides.2007.06.013
1999, J Ocul Pharmacol Ther, 15, 389, 10.1089/jop.1999.15.389
10.1016/j.neulet.2008.10.021
10.1016/j.regpep.2008.07.004
10.1016/j.pain.2008.10.028
2001, Am J Physiol Gastrointest Liver Physiol, 281, G997, 10.1152/ajpgi.2001.281.4.G997
1993, Eur J Pharmacol, 243, 291, 10.1016/0014-2999(93)90188-N
10.1016/S0169-328X(00)00219-9
1994, J Neuroendocrinol, 6, 549, 10.1111/j.1365-2826.1994.tb00618.x
10.1046/j.1365-2826.1997.00580.x
10.1016/0196-9781(92)90068-E
10.1016/0303-7207(95)03752-7
1993, Eur J Biochem, 217, 823, 10.1111/j.1432-1033.1993.tb18310.x
1991, Eur J Biochem, 202, 951, 10.1111/j.1432-1033.1991.tb16455.x
1994, Z Gastroenterol, 32, 208
10.1016/S0167-0115(98)00147-5
1993, Pancreas, 8, 476, 10.1097/00006676-199307000-00012
Schmidt-Choudhury, A , Furuta, GT, Galli, SJ, Schmidt, WE Wershil, BK(1999a)Mast cells contribute to PACAP-induced dermal oedema in mice. Regul Pept 82: 65–69.
Schmidt-Choudhury, A , Meissner, J, Seebeck, J, Goetzl, EJ, Xia, M, Galli, SJ, Schmidt, WE, Schaub, J Wershil, BK(1999b)Stem cell factor influences neuro-immune interactions: the response of mast cells to pituitary adenylate cyclase activating polypeptide is altered by stem cell factor. Regul Pept 83: 73–80.
10.1016/S0006-8993(99)01533-4
10.1007/s00441-002-0588-x
10.1158/1078-0432.CCR-04-0939
1992, Naunyn Schmiedebergs Arch Pharmacol, 346, 511
10.1016/S0014-2999(98)00372-0
10.1523/JNEUROSCI.0158-05.2005
10.1016/1043-2760(93)90071-L
10.1016/S0006-8993(99)01909-5
10.1016/0300-9084(94)90147-3
10.1111/j.1749-6632.1998.tb10727.x
10.1016/S0196-9781(99)00180-1
10.1016/S0304-3940(97)00869-0
Seki, Y , Suzuki, Y, Baskaya, MK, Kano, T, Saito, K, Takayasu, M, Shibuya, M Sugita, K(1995a)The effects of pituitary adenylate cyclase-activating polypeptide on cerebral arteries and vertebral artery blood flow in anesthetized dogs. Eur J Pharmacol 275: 259–266.
Seki, Y , Suzuki, Y, Baskaya, MK, Saito, K, Takayasu, M, Shibuya, M Sugita, K(1995b)Central cardiovascular effects induced by intracisternal PACAP in dogs. Am J Physiol 269: 135–139.
10.1016/0024-3205(94)00661-X
10.1016/j.regpep.2003.10.002
Shen, S , Spratt, C, Sheward, WJ, Kallo, I, West, K, Morrison, CF, Coen, CW, Marston, HM Harmar, AJ (2000)97:Proc Natl Acad Sci U S A11575–11580.
10.1016/j.peptides.2007.03.008
10.1016/0306-4522(95)00048-N
10.1016/0304-3940(96)13002-0
1998, Brain ResDev Brain Res, 109, 245, 10.1016/S0165-3806(98)00086-8
Shibuya, I , Kabashima, N, Tanaka, K, Setiadji, VS, Noguchi, J, Harayama, N, Ueta, Y Yamashita, H(1998a)Patch-clamp analysis of the mechanism of PACAP-induced excitation in rat supraoptic neurones. J Neuroendocrinol 10: 759–768.
Shibuya, I , Noguchi, J, Tanaka, K, Harayama, N, Inoue, U, Kabashima, N, Ueta, Y, Hattori, Y Yamashita, H(1998b)PACAP increases the cytosolic Ca2+ concentration and stimulates somatodendritic vasopressin release in rat supraoptic neurons. J Neuroendocrinol 10: 31–42.
1999, J Neurochem, 73, 2167, 10.1046/j.1471-4159.1999.02167.x
10.1183/09031936.98.12010064
10.1016/0167-0115(96)00026-2
10.1016/j.regpep.2004.05.019
1999, Mol Brain Res, 63, 262, 10.1016/S0169-328X(98)00289-7
10.1016/S0306-4522(01)00479-1
2000, Biochim Biophys Acta, 1509, 195, 10.1016/S0005-2736(00)00295-9
10.1016/S0167-0115(02)00169-6
10.1016/j.regpep.2004.08.014
10.1016/j.lfs.2003.09.021
2000, Kaibogaku Zasshi, 75, 487
1996, Ann N Y Acad Sci, 805, 677
Shioda, S , Nakai, Y, Nakajo, S, Nakaya, K Arimura, A(1996b)Pituitary adenylate cyclase-activating polypeptide and its type I receptors in the rat hypothalamus: neuroendocrine interactions. Ann N Y Acad Sci 805: 670–676.
10.1016/S0304-3940(00)01595-0
Shioda, S , Shuto, Y, Somogyvari-Vigh, A, Legradi, G, Onda, H, Coy, DH, Nakajo, S Arimura, A(1997a)Localization and gene expression of the receptor for pituitary adenylate cyclase-activating polypeptide in the rat brain. Neurosci Res 28: 345–354.
Shioda, S , Yada, T, Nakajo, S, Nakaya, K, Nakai, Y Arimura, A(1997b)Pituitary adenylate cyclase-activating polypeptide (PACAP): a novel regulator of vasopressin-containing neurons. Brain Res 765: 81–90.
Shioda, S , Zhou, CJ, Ohtaki, H Yada, TVaudry, H, Arimura, A & Melmed, S (2003) ACAP receptor signaling, inPituitary Adenylate Cyclase-Activating PolypeptideKluwer Academic Publishers,Amsterdam.95–124,
10.1016/0196-9781(95)00076-V
10.1016/S0006-8993(99)01690-X
10.1016/0196-9781(95)00080-4
10.1016/S0167-0115(96)00116-4
10.1016/S0306-4522(97)00668-4
10.1016/0006-8993(93)91313-H
10.1016/S0378-1119(99)00286-3
10.1016/S0306-4522(98)00414-X
10.1016/S0304-3940(99)00250-5
1999, Mol Brain Res, 65, 1, 10.1016/S0169-328X(98)00294-0
1998, J Immunol, 160, 1811, 10.4049/jimmunol.160.4.1811
10.1016/S0898-6568(99)00052-2
10.1016/S0167-0115(02)00164-7
10.1016/S0167-0115(00)00123-3
10.1016/S0026-0495(96)90079-7
10.1016/S1532-0456(01)00177-6
Sreedharan, SP , Huang, JX, Cheung, MC Goetzl, EJ (1995)92:Proc Natl Acad Sci U S A2939–2943.
10.1016/0006-8993(85)90691-2
1995, Am J Physiol, 269, E108
10.1016/0167-0115(95)00156-5
1994, Acta Physiol Scand, 152, 129, 10.1111/j.1748-1716.1994.tb09792.x
1976, Ann Surg, 184, 107, 10.1097/00000658-197607000-00018
Ster, J , De Bock, F, Guérineau, NC, Janossy, A, Barrère-Lemaire, S, Bos, JL, Bockaert, J Fagni, L (2007)104:Proc Natl Acad Sci U S A2519–2524.
10.1016/S0143-4179(97)90082-2
10.1111/j.1471-4159.2007.04895.x
10.1016/0304-3940(92)90288-I
10.1016/j.regpep.2004.05.008
10.1016/j.brainres.2004.08.017
Sun, C , Song, D, Davis-Taber, RA, Barrett, LW, Scott, VE, Richardson, PL, Pereda-Lopez, A, Uchic, ME, Solomon, LR, Lake, MR, et al.(2007)104:Proc Natl Acad Sci U S A7875–7880.
10.1016/0306-4522(92)90064-9
1994, Eur J Biochem, 223, 147, 10.1111/j.1432-1033.1994.tb18976.x
1993, J Biochem, 113, 549, 10.1093/oxfordjournals.jbchem.a124081
2003, Mol Brain Res, 115, 10, 10.1016/S0169-328X(03)00172-4
10.1016/0196-9781(86)90157-9
10.1016/S0167-0115(02)00185-4
10.1152/ajplung.00499.2005
Tabuchi, A , Koizumi, M Tsuda, M(2001b)Novel splice variants of PACAP gene in mouse cerebellar granule cells. Neuroreport 12: 1181–1186.
Tabuchi, A , Koizumi, M, Nakatsubo, J, Yaguchi, T Tsuda, M(2001a)Involvement of endogenous PACAP expression in the activity-dependent survival of mouse cerebellar granule cells. Neurosci Res 39: 85–93.
10.1016/S0304-3940(03)00017-X
10.1046/j.1468-2982.2001.00140.x
10.1016/0167-0115(94)90007-8
Takahashi, K , Totsune, K, Murakami, O, Sone, M, Itoi, K, Hayashi, Y, Ohi, R Mouri, T(1993a)Pituitary adenylate cyclase activating polypeptide (PACAP)-like immunoreactivity in ganglioneuroblastoma and neuroblastoma. Regul Pept 49: 19–24.
Takahashi, K , Totsune, K, Murakami, O, Sone, M, Itoi, K, Miura, Y Mouri, T(1993b)Pituitary adenylate cyclase activating polypeptide (PACAP)-like immunoreactivity in pheochromocytomas. Peptides 14: 365–369.
10.1002/(SICI)1097-4547(19981201)54:5<698::AID-JNR15>3.0.CO;2-5
1997, Am J Physiol, 272, G646
10.1111/j.1365-2982.2005.00733.x
10.1016/j.regpep.2003.10.033
10.1016/j.peptides.2007.07.011
10.1016/0304-3940(94)90498-7
10.1016/S0196-9781(98)00107-7
Tan, YV , Abad, C, Lopez, R, Dong, H, Liu, S, Lee, A, Gomariz, RP, Leceta, J Waschek, JA (2009)106:Proc Natl Acad Sci U S A2012–2017.
Tanaka, J , Koshimura, K, Murakami, Y, Sohmiya, M, Yanaihara, N Kato, Y(1997a)Neuronal protection from apoptosis by pituitary adenylate cyclase-activating polypeptide. Regul Pept 72: 1–8.
Tanaka, K , Shibuya, I, Harayama, N, Nomura, M, Kabashima, N, Ueta, Y Yamashita, H(1997b)Pituitary adenylate cyclase-activating polypeptide potentiation of Ca2+ entry via protein kinase C and A pathways in melanotrophs of the pituitary pars intermedia of rats. Endocrinology 138: 4086–4095.
1998, J Neurochem, 70, 1652, 10.1046/j.1471-4159.1998.70041652.x
10.1523/JNEUROSCI.4376-05.2006
10.1016/0006-8993(94)90790-0
Tatsuno, I , Gottschall, PE Arimura, A(1991a)Inhibition of mitogen-stimulated proliferation of murine splenocytes by a novel neuropeptide, pituitary adenylate cyclase activating polypeptide: a comparative study with vasoactive intestinal peptide. Endocrinology 128: 728–734.
Tatsuno, I , Gottschall, PE Arimura, A(1991b)Specific binding sites for pituitary adenylate cyclase activating polypeptide (PACAP) in rat cultured astrocytes: molecular identification and interaction with vasoactive intestinal peptide (VIP). Peptides 12: 617–621.
10.1016/0006-291X(90)91132-C
10.1016/0196-9781(94)90170-8
Tatsuno, I , Somogyvari-Vigh, A, Mizuno, K, Gottschall, PE, Hidaka, H Arimura, A(1991c)Neuropeptide regulation of interleukin-6 production from the pituitary: stimulation by pituitary adenylate cyclase activating polypeptide and calcitonin gene-related peptide. Endocrinology 129: 1797–1804.
1999, Hypertension, 34, 1152, 10.1161/01.HYP.34.5.1152
10.1016/S0167-0115(98)00112-8
10.1016/0304-3940(95)11472-9
10.1016/0306-4522(94)00622-C
10.1016/S0304-3940(97)00649-6
10.1016/j.regpep.2004.04.028
10.1007/s12031-008-9127-x
10.1007/s12031-008-9086-2
10.1113/jphysiol.2007.134965
Tong, S , Parfenova, H, Shibata, M, Zuckerman, S, Armstead, WM Leffler, CW (1993)203:Proc Soc Exp Biol Med343–347.
1997, J Mol Neurosci, 9, 127, 10.1007/BF02736856
10.1016/S0923-1811(99)00004-3
1997, Am J Physiol, 273, G436
10.1016/S0167-0115(01)00276-2
2000, Am J Physiol Endocrinol Metab, 279, E1413, 10.1152/ajpendo.2000.279.6.E1413
1994, Clin Exp Rheumatol, 12, 287
10.1007/s00424-005-1491-6
10.1016/0024-3205(95)00047-A
10.1016/0303-7207(95)03613-C
10.1016/0006-8993(96)00716-0
10.1111/j.1749-6632.1998.tb11185.x
10.1111/j.1365-2826.1996.tb00834.x
10.1016/0167-0115(91)90074-Q
10.1016/S0006-8993(99)01260-3
10.1016/j.brainres.2006.09.103
Vandepoele, K , De Vos, W, Taylor, JS, Meyer, A Van de Peer, Y (2004)101:Proc Natl Acad Sci U S A1638–1643.
1992, Eur J Biochem, 208, 815, 10.1111/j.1432-1033.1992.tb17252.x
10.1016/0006-8993(87)91625-8
10.1046/j.1365-2826.1998.00186.x
10.1111/j.1749-6632.2002.tb04509.x
Vaudry, D , Basille, M, Anouar, Y, Fournier, A, Vaudry, H Gonzalez, BJ(1998a)The neurotrophic activity of PACAP on rat cerebellar granule cells is associated with activation of the protein kinase A pathway and c-fos gene expression. Ann N Y Acad Sci 865: 92–99.
Vaudry, D , Chen, Y, Hsu, CM Eiden, LE(2002a)PC12 cells as a model to study the neurotrophic activities of PACAP. Ann N Y Acad Sci 971: 491–496.
Vaudry, D , Chen, Y, Ravni, A, Hamelink, C, Elkahloun, AG Eiden, LE(2002b)Analysis of the PC12 cell transcriptome after differentiation with pituitary adenylate cyclase-activating polypeptide (PACAP). J Neurochem 83: 1272–1284.
Vaudry, D , Falluel-Morel, A, Basille, M, Pamantung, TF, Fontaine, M, Fournier, A, Vaudry, H Gonzalez, BJ(2003a)Pituitary adenylate cyclase-activating polypeptide prevents C2-ceramide-induced apoptosis of cerebellar granule cells. J Neurosci Res 72: 303–316.
Vaudry, D , Falluel-Morel, A, Leuillet, S, Vaudry, H Gonzalez, BJ(2003b)Regulators of cerebellar granule cell development act through specific signaling pathways. Science 300: 1532–1534.
Vaudry, D , Gonzalez, BJ, Basille, M, Anouar, Y, Fournier, A Vaudry, H(1998b)Pituitary adenylate cyclase-activating polypeptide stimulates both c-fos gene expression and cell survival in rat cerebellar granule neurons through activation of the protein kinase A pathway. Neuroscience 84: 801–812.
Vaudry, D , Gonzalez, BJ, Basille, M, Fournier, A Vaudry, H (1999)96:Proc Natl Acad Sci U S A9415–9420.
Vaudry, D , Gonzalez, BJ, Basille, M, Pamantung, TF, Fontaine, M, Fournier, A Vaudry, H (2000a)97:Proc Natl Acad Sci U S A13390–13395.
Vaudry, D , Gonzalez, BJ, Basille, M, Pamantung, TF, Fournier, A Vaudry, H(2000b)PACAP acts as a neurotrophic factor during histogenesis of the rat cerebellar cortex. Ann N Y Acad Sci 921: 293–299.
2000, Pharmacol Rev, 52, 269
10.1016/j.peptides.2005.05.015
Vaudry, D , Pamantung, TF, Basille, M, Rousselle, C, Fournier, A, Vaudry, H, Beauvillain, JC Gonzalez, BJ(2002c)PACAP protects cerebellar granule neurons against oxidative stress-induced apoptosis. Eur J Neurosci 15: 1451–1460.
Vaudry, D , Rousselle, C, Basille, M, Falluel-Morel, A, Pamantung, TF, Fontaine, M, Fournier, A, Vaudry, H Gonzalez, BJ (2002d)99:Proc Natl Acad Sci U S A6398–6403.
Vaudry, D , Stork, PJ, Lazarovici, P Eiden, LE(2002e)Signaling pathways for PC12 cell differentiation: making the right connections. Science 296: 1648–1649.
10.1016/S0143-4179(96)90015-3
Vertongen, P , d'Haens, J, Michotte, A, Velkeniers, B, van Rampelbergh, J, Svoboda, M Robberecht, P(1995a)Expression of pituitary adenylate cyclase activating polypeptide and receptors in human brain tumors. Peptides 16: 713–719.
Vertongen, P , De Clerck, P, Fournet, JC, Martelli, H, Hélardot, P, Devalck, C, Peeters, T, Sariban, E Robberecht, P(1997a)Comparison between vasoactive intestinal polypeptide and pituitary adenylate cyclase activating polypeptide levels in neuroblastoma tumour tissues. Neuropeptides 31: 409–413.
Vertongen, P , Schiffmann, SN, Gourlet, P Robberecht, P(1997b)Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain. Peptides 18: 1547–1554.
10.1111/j.1749-6632.1998.tb11206.x
Vertongen, P , Velkeniers, B, Hooghe-Peters, E Robberecht, P(1995b)Differential alternative splicing of PACAP receptor in pituitary cell subpopulations. Mol Cell Endocrinol 113: 131–135.
10.1016/0196-9781(93)90011-5
10.1016/0196-9781(91)90018-K
1997, J Neurosci, 17, 83, 10.1523/JNEUROSCI.17-01-00083.1997
10.1016/S0928-4257(01)00014-6
10.1016/S0196-9781(99)00084-4
1998, J Nucl Med, 39, 1575
1998, J Neurosci, 18, 10389, 10.1523/JNEUROSCI.18-24-10389.1998
1981, Biochim Biophys Acta, 678, 83, 10.1016/0304-4165(81)90050-7
10.1016/S0196-9781(97)00257-X
Wallengren, J (1997)2:J Investig Dermatol Symp Proc49–55.
10.1016/j.febslet.2005.06.013
10.1016/S0167-0115(99)00068-3
10.1016/0306-4522(95)00258-K
Warren, JB , Cockcroft, JR, Larkin, SW, Kajekar, R, Macrae, A, Ghatei, MA Bloom, SR(1992a)Pituitary adenylate cyclase activating polypeptide is a potent vasodilator in humans. J Cardiovasc Pharmacol 20: 83–87.
10.1016/0014-2999(91)90511-N
1992, Br J Pharmacol, 106, 331, 10.1111/j.1476-5381.1992.tb14336.x
Waschek, JA , Bravo, DT Richards, ML(1995a)High levels of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor mRNA expression in primary and tumor lymphoid cells. Regul Pept 60: 149–157.
Waschek, JA , Casillas, RA, Nguyen, TB, DiCicco-Bloom, EM, Carpenter, EM Rodriguez, WI (1998)95:Proc Natl Acad Sci U S A9602–9607.
2000, ANN N YAcad Sci, 921, 129, 10.1111/j.1749-6632.2000.tb06959.x
1996, J Neurochem, 66, 1762, 10.1046/j.1471-4159.1996.66041762.x
10.1016/S0196-9781(97)00015-6
Waschek, JA , Richards, ML Bravo, DT(1995b)Differential expression of VIP/PACAP receptor genes in breast, intestinal, and pancreatic cell lines. Cancer Lett 92: 143–149.
10.1016/j.peptides.2007.06.029
10.1016/S0006-291X(05)80159-7
10.1016/S0006-291X(05)81049-6
1995, Am J Physiol, 269, E903
Wei, Y Mojsov, S(1996a)Distribution of GLP-1 and PACAP receptors in human tissues. Acta Physiol Scand 157: 355–357.
Wei, Y Mojsov, S(1996b)Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology. J Neuroendocrinol 8: 811–817.
Whalen, EJ , Johnson, AK Lewis, SJ(1999a)Hemodynamic actions of systemically injected pituitary adenylate cyclase activating polypeptide-27 in the rat. Eur J Pharmacol 365: 205–215.
Whalen, EJ , Johnson, AK Lewis, SJ(1999b)Tachyphylaxis to PACAP-27 after inhibition of NO synthesis: a loss of adenylate cyclase activation. Am J Physiol 277: R1453–1461.
Whalen, EJ , Travis, MD, Johnson, AK Lewis, SJ(1999c)Rapid tachyphylaxis to hemodynamic effects of PACAP-27 after inhibition of nitric oxide synthesis. Am J Physiol 276: 2117–2126.
1997, Exp Physiol, 82, 729, 10.1113/expphysiol.1997.sp004061
2000, Ann N Y Acad Sci, 921, 370, 10.1111/j.1749-6632.2000.tb06996.x
10.1016/0196-9781(88)90218-5
1997, Am J Physiol, 272, 1350
1993, Br J Pharmacol, 110, 633, 10.1111/j.1476-5381.1993.tb13858.x
10.1016/j.resp.2008.06.003
1997, Exp Physiol, 82, 871, 10.1113/expphysiol.1997.sp004070
10.1016/j.peptides.2007.04.024
10.1016/0304-3940(95)12116-L
1995, Biomed Pept Proteins Nucleic Acids, 1, 77
1997, J Pharmacol Exp Ther, 281, 629
10.1016/0165-5728(94)90231-3
10.1111/j.1471-4159.2007.04468.x
10.1007/978-0-387-73693-8_12
10.1016/j.peptides.2008.12.010
1997, Jpn J Physiol, 47, S27
1994, J Biol Chem, 269, 1290, 10.1016/S0021-9258(17)42256-3
Yada, T , Sakurada, M, Ishihara, H, Nakata, M, Shioda, S, Yaekura, K, Hamakawa, N, Yanagida, K, Kikuchi, M Oka, Y(1997b)Pituitary adenylate cyclase-activating polypeptide (PACAP) is an islet substance serving as an intra-islet amplifier of glucose-induced insulin secretion in rats. J Physiol 505: 319–328.
Yada, T , Sakurada, M, Nakata, M, Yaekura, K Kikuchi, M(1997c)PACAP as low as 10(13) M raises cytosolic Ca2+ activity in pancreatic B-cells by augmenting Ca2+ influx through L-type Ca2+ channels to trigger insulin release. Adv Exp Med Biol 426: 165–171.
10.1016/0196-9781(93)90035-F
10.1016/S0378-1119(98)00110-3
2003, Diabetes, 52, 1155, 10.2337/diabetes.52.5.1155
10.1016/0304-3940(95)11470-H
10.1016/S0167-0115(98)00125-6
Yang, K , Trepanier, CH, Li, H, Beazely, MA, Lerner, EA, Jackson, MF Macdonald, JF (2009) asoactive intestinal peptide acts via multiple signal pathways to regulate hippocampal NMDA receptors and synaptic transmission. Hippocampus.In press.
10.1016/j.neulet.2007.08.037
10.1016/0196-9781(96)00080-0
10.1016/0891-0618(91)90024-7
10.1016/0196-9781(94)00143-T
10.1111/j.1365-2826.1993.tb00485.x
10.1016/j.regpep.2004.04.023
10.1016/S0165-3806(01)00249-8
1995, J Neurochem, 64, 2273, 10.1046/j.1471-4159.1995.64052273.x
1994, Comp Biochem Physiol C Pharmacol Toxicol Endocrinol, 109, 93, 10.1016/0742-8413(94)00036-A
10.1016/S0304-3940(02)01397-6
Zeng, N , Athmann, C, Kang, T, Lyu, RM, Walsh, JH, Ohning, GV, Sachs, G Pisegna, JR(1999a)PACAP type I receptor activation regulates ECL cells and gastric acid secretion. J Clin Invest 104: 1383–1391.
Zeng, N , Athmann, C, Kang, T, Walsh, JH Sachs, G(1999b)Role of neuropeptide-sensitive L-type Ca2+ channels in histamine release in gastric enterochromaffin-like cells. Am J Physiol 277: G1268–1280.
10.1111/j.1749-6632.1998.tb11173.x
10.1016/0304-3940(94)90582-7
10.1016/j.regpep.2007.06.008
1993, Am J Physiol, 264, E933
10.1111/j.1471-4159.2007.04813.x
10.1097/00001756-199808240-00027
1996, Neuroscience, 74, 1099, 10.1016/0306-4522(96)00168-6
1994, J Neurosci, 14, 4656, 10.1523/JNEUROSCI.14-08-04656.1994
2000, Mol Brain Res, 75, 150, 10.1016/S0169-328X(99)00300-9
Zhou, CJ , Shioda, S, Shibanuma, M, Nakajo, S, Funahashi, H, Nakai, Y, Arimura, A Kikuyama, S(1999a)Pituitary adenylate cyclase-activating polypeptide receptors during development: expression in the rat embryo at primitive streak stage. Neuroscience 93: 375–391.
Zhou, X , Rodriguez, WI, Casillas, RA, Ma, V, Tam, J, Hu, Z, Lelievre, V, Chao, A Waschek, JA(1999b)Axotomy-induced changes in pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP receptor gene expression in the adult rat facial motor nucleus. J Neurosci Res 57: 953–961.
10.1182/blood-2008-05-078154
1995, Cancer Res, 55, 4886
10.1016/0196-9781(88)90188-X
10.1016/0306-4522(89)90440-5
10.1016/j.neulet.2004.01.030
10.1016/j.neuropharm.2003.09.011
10.1016/j.ejphar.2005.08.027
1998, J Neurochem, 70, 2165, 10.1046/j.1471-4159.1998.70052165.x
10.1016/j.regpep.2004.05.021
10.1016/j.expneurol.2004.10.017
